Avalon’s Take on This Week’s News
For a while, it has felt like nobody is in charge of public health. In some key roles, nobody has been. Just after we pushed out the last newsletter, though, the administration finally nominated a new CDC Director. While the overall dynamics of this moment are not changing anytime soon, this is a meaningful step and one that comes after months of disrupted USPSTF activity, vaccine policy fights in courtrooms, and substantial pressure on federal research funding. If the goal is a clear, durable approach to prevention, we are not there yet.
And yet, alongside that instability, innovation continues ahead anyway. Blood-based Alzheimer’s testing is gaining traction despite limited treatment options, driven largely by patient demand to know even when little can be done with the answer. At the same time, CMS and FDA are working to tighten the gap between approval and coverage for new technologies. Consumer testing is also moving further into everyday use—WHOOP might tell us Rory McIlroy’s heart rate at The Masters, sure—but what it’s really building toward is a world where you know more and more about your body and still are not sure what to do next.
Meanwhile, and despite the centrality of efficiency as a talking point, the administrative layers keep thickening. Courts are affirming the role of intermediaries in IDR disputes under the No Surprises Act, while payers push forward on prior authorization “standardization” that still lacks a clear endpoint. And speaking of provider-payer fights, the push for site-neutral payment reform continues, with hospital groups fighting against it while simultaneously emphasizing affordability. Everyone agrees the current system is inefficient. Agreement tends to stop there.
In the middle of all of this is AI. Some tools are proving useful, though others are getting pulled back once they hit real workflows. Regulators and legislators, at the state level in particular, are asking harder questions, which suggests the gap between capability and comfort is still very real. Regardless of comfort, innovation and deployment abound without much in the way of an agreed-upon framework.
At this moment, the reality is that different parts of the system are working from the same data and arriving at very different conclusions about risk and value. The friction stems from misalignment across the system. Without a clear framework, decision-making keeps fragmenting. The themes are consistent enough to suggest a map, but each week adds new landmines. Helpful, in the way a map of a minefield is helpful.
Key Developments
- CDC nomination follows months of institutional drift
A new CDC Director has been nominated after a prolonged gap, following disruption to USPSTF activity and continued legal and political pressure on vaccine policy.
- Alzheimer’s testing demand is outpacing treatment reality
Blood-based diagnostics for Alzheimer’s are gaining adoption, even as therapeutic options remain limited—highlighting a growing gap between the desire for information and the ability to act.
- Court decisions are reshaping how payment disputes actually play out
Recent rulings are allowing a broader set of intermediaries to participate in IDR under the No Surprises Act, reinforcing a system where resolution is increasingly driven by process and positioning—not just underlying claims.
- AI is running into real-world constraints faster than expected
Several high-profile pilots—from clinical tools to utilization workflows—have already been paused or scaled back after deployment, highlighting the gap between controlled environments and actual care settings.
Strategic Takeaway
There’s no shortage of innovation in the system right now. What’s harder to find is alignment. As federal institutions work through their own transitions, more of the real decision-making is happening on the ground. Coverage, utilization, and diagnostic strategy are increasingly shaped by the organizations running the system day to day.
Adopting new capabilities is the easier part. The harder work is deciding how to apply them in a system where the same data can support competing conclusions, and being ready to defend those choices when someone, say a regulator, asks why. In that environment, control over how data is interpreted and applied matters more than who generates it.
